Prime Medicine, Inc. (PRME): Total Liabilities
$221.87M
As of 2025-12-31
$209.23M
As of 2026-06-30
+71.4%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $221.87M | +53.7% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $144.36M | +137.5% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $60.78M | +38.0% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $44.04M | -29.3% | 2024-03-01, Balance as of period end |
| 2021-12-31 | $62.30M | n/a | 2023-03-09, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $221.87M | +53.7% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $55.68M | +5.4% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $2.95M | -10.5% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $38.99M | +82.0% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $64.95M | +69.7% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $343.43M | +10.8% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $286.49M | +310.2% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $8.71M | +16.8% |
| Curis Inc (CRIS) | 2025-12-31 | $14.50M | -69.3% |
Compare PRME, OCGN, ZEOX, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗